KR100596257B1 - 스테롤 흡수 억제제를 포함하는 조성물, 및 페록시솜 증식인자-활성화 수용체 활성화제와 스테롤 흡수 억제제를 포함하는 조성물 및 조합물 - Google Patents

Info

Publication number

KR100596257B1

KR100596257B1 KR1020037009749A KR20037009749A KR100596257B1 KR 100596257 B1 KR100596257 B1 KR 100596257B1 KR 1020037009749 A KR1020037009749 A KR 1020037009749A KR 20037009749 A KR20037009749 A KR 20037009749A KR 100596257 B1 KR100596257 B1 KR 100596257B1

Authority

KR

South Korea

Prior art keywords

delete delete

substituted

alkyl

compounds

group

Prior art date

2001-01-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 229930182558 Sterol Natural products 0.000 title claims abstract description 66
• 235000003702 sterols Nutrition 0.000 title claims abstract description 66
• 150000003432 sterols Chemical class 0.000 title claims abstract description 63
• 239000003102 growth factor Substances 0.000 title claims abstract description 41
• 108091006084 receptor activators Proteins 0.000 title claims abstract description 41
• 239000000203 mixture Substances 0.000 title claims description 106
• 239000003112 inhibitor Substances 0.000 title abstract description 74
• 238000010521 absorption reaction Methods 0.000 title description 36
• 230000000858 peroxisomal effect Effects 0.000 title description 4
• 208000008589 Obesity Diseases 0.000 claims abstract description 15
• 235000020824 obesity Nutrition 0.000 claims abstract description 15
• 208000019553 vascular disease Diseases 0.000 claims abstract description 14
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
• 241000124008 Mammalia Species 0.000 claims description 13
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 10
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
• 229940069328 povidone Drugs 0.000 claims description 3
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
• 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
• 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
• 229960001021 lactose monohydrate Drugs 0.000 claims description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
• 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
• 239000001913 cellulose Substances 0.000 claims 1
• 235000010980 cellulose Nutrition 0.000 claims 1
• 229920002678 cellulose Polymers 0.000 claims 1
• 229960001375 lactose Drugs 0.000 claims 1
• 239000008101 lactose Substances 0.000 claims 1
• 235000019359 magnesium stearate Nutrition 0.000 claims 1
• -1 β-lactam sterol Chemical class 0.000 abstract description 178
• MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract description 56
• 239000003814 drug Substances 0.000 abstract description 43
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 18
• 229940124597 therapeutic agent Drugs 0.000 abstract description 12
• 239000003795 chemical substances by application Substances 0.000 abstract description 10
• 230000036470 plasma concentration Effects 0.000 abstract description 4
• 150000001875 compounds Chemical class 0.000 description 230
• 125000000217 alkyl group Chemical group 0.000 description 129
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 103
• 229910052739 hydrogen Inorganic materials 0.000 description 91
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 80
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 74
• 150000003839 salts Chemical class 0.000 description 74
• 125000003118 aryl group Chemical group 0.000 description 72
• 239000001257 hydrogen Substances 0.000 description 61
• 239000012453 solvate Substances 0.000 description 60
• 230000001225 therapeutic effect Effects 0.000 description 55
• 125000005843 halogen group Chemical class 0.000 description 54
• 125000001424 substituent group Chemical group 0.000 description 53
• 229940002612 prodrug Drugs 0.000 description 52
• 239000000651 prodrug Substances 0.000 description 52
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 40
• PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 description 35
• 238000000034 method Methods 0.000 description 35
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 33
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
• 235000012000 cholesterol Nutrition 0.000 description 28
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 28
• 239000012190 activator Substances 0.000 description 27
• 125000003545 alkoxy group Chemical group 0.000 description 26
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 26
• 125000002947 alkylene group Chemical group 0.000 description 24
• 125000001072 heteroaryl group Chemical group 0.000 description 24
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 20
• 230000015572 biosynthetic process Effects 0.000 description 20
• 229910052799 carbon Inorganic materials 0.000 description 20
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 16
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 16
• 238000011260 co-administration Methods 0.000 description 15
• 229910052736 halogen Inorganic materials 0.000 description 15
• 150000002367 halogens Chemical group 0.000 description 15
• 239000000243 solution Substances 0.000 description 15
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 14
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
• 108010007622 LDL Lipoproteins Proteins 0.000 description 14
• 102000007330 LDL Lipoproteins Human genes 0.000 description 14
• 125000001797 benzyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 14
• 239000011541 reaction mixture Substances 0.000 description 14
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 13
• 239000000460 chlorine Substances 0.000 description 13
• 229940079593 drug Drugs 0.000 description 13
• 229940011871 estrogen Drugs 0.000 description 13
• 239000000262 estrogen Substances 0.000 description 13
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• 125000003003 spiro group Chemical group 0.000 description 13
• 125000001544 thienyl group Chemical group 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 12
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 12
• 125000004432 carbon atom Chemical group C* 0.000 description 12
• 125000004076 pyridyl group Chemical group 0.000 description 12
• 229910052708 sodium Inorganic materials 0.000 description 12
• 239000011734 sodium Substances 0.000 description 12
• 238000011282 treatment Methods 0.000 description 12
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 11
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
• 239000003826 tablet Substances 0.000 description 11
• 201000001320 Atherosclerosis Diseases 0.000 description 10
• 102000023984 PPAR alpha Human genes 0.000 description 10
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 10
• 229940125753 fibrate Drugs 0.000 description 10
• 125000001153 fluoro group Chemical group F* 0.000 description 10
• 125000002541 furyl group Chemical group 0.000 description 10
• 125000002883 imidazolyl group Chemical group 0.000 description 10
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 10
• 125000003226 pyrazolyl group Chemical group 0.000 description 10
• 125000000168 pyrrolyl group Chemical group 0.000 description 10
• 125000000335 thiazolyl group Chemical group 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• 108010016731 PPAR gamma Proteins 0.000 description 9
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 9
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• 201000010099 disease Diseases 0.000 description 9
• 210000004185 liver Anatomy 0.000 description 9
• 125000002757 morpholinyl group Chemical group 0.000 description 9
• 229910052757 nitrogen Inorganic materials 0.000 description 9
• 125000003386 piperidinyl group Chemical group 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
• 125000003282 alkyl amino group Chemical group 0.000 description 8
• 239000003613 bile acid Substances 0.000 description 8
• 229960002568 ethinylestradiol Drugs 0.000 description 8
• 229960002297 fenofibrate Drugs 0.000 description 8
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 8
• 125000000842 isoxazolyl group Chemical group 0.000 description 8
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 8
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 8
• 125000000714 pyrimidinyl group Chemical group 0.000 description 8
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 8
• WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 7
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 7
• 239000005977 Ethylene Substances 0.000 description 7
• 108010010234 HDL Lipoproteins Proteins 0.000 description 7
• 102000015779 HDL Lipoproteins Human genes 0.000 description 7
• 108010015181 PPAR delta Proteins 0.000 description 7
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
• 229920000080 bile acid sequestrant Polymers 0.000 description 7
• 239000002775 capsule Substances 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 7
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
• 125000001624 naphthyl group Chemical group 0.000 description 7
• 235000001968 nicotinic acid Nutrition 0.000 description 7
• 239000011664 nicotinic acid Substances 0.000 description 7
• 239000000583 progesterone congener Substances 0.000 description 7
• 125000003373 pyrazinyl group Chemical group 0.000 description 7
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 7
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 6
• ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 241000196324 Embryophyta Species 0.000 description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 6
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 6
• 208000035150 Hypercholesterolemia Diseases 0.000 description 6
• 125000004450 alkenylene group Chemical group 0.000 description 6
• 125000005605 benzo group Chemical group 0.000 description 6
• 229940096699 bile acid sequestrants Drugs 0.000 description 6
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 6
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
• 229960003512 nicotinic acid Drugs 0.000 description 6
• 239000012044 organic layer Substances 0.000 description 6
• 125000002971 oxazolyl group Chemical group 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 6
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 5
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 5
• DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 5
• 108010001831 LDL receptors Proteins 0.000 description 5
• 102000000853 LDL receptors Human genes 0.000 description 5
• 102000004895 Lipoproteins Human genes 0.000 description 5
• 108090001030 Lipoproteins Proteins 0.000 description 5
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 5
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
• 125000000051 benzyloxy group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 125000001309 chloro group Chemical group Cl* 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 5
• 230000000144 pharmacologic effect Effects 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 229960002855 simvastatin Drugs 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 4
• 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 4
• 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 4
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 4
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 4
• 208000031226 Hyperlipidaemia Diseases 0.000 description 4
• 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 4
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
• 125000004414 alkyl thio group Chemical group 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 229940125708 antidiabetic agent Drugs 0.000 description 4
• 239000003472 antidiabetic agent Substances 0.000 description 4
• 239000003963 antioxidant agent Substances 0.000 description 4
• 235000006708 antioxidants Nutrition 0.000 description 4
• 125000004104 aryloxy group Chemical class 0.000 description 4
• 125000004429 atom Chemical group 0.000 description 4
• 125000002047 benzodioxolyl group Chemical class O1OC(C2=C1C=CC=C2)* 0.000 description 4
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
• 150000001721 carbon Chemical group 0.000 description 4
• 208000029078 coronary artery disease Diseases 0.000 description 4
• 230000000875 corresponding effect Effects 0.000 description 4
• 125000000753 cycloalkyl group Chemical group 0.000 description 4
• 125000005879 dioxolanyl group Chemical group 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 4
• 239000012458 free base Substances 0.000 description 4
• 229960003627 gemfibrozil Drugs 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 125000001786 isothiazolyl group Chemical group 0.000 description 4
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 125000004043 oxo group Chemical group O=* 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 239000002831 pharmacologic agent Substances 0.000 description 4
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 4
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 4
• FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 4
• 229960003912 probucol Drugs 0.000 description 4
• 125000002098 pyridazinyl group Chemical group 0.000 description 4
• 229960000747 sodium estrone sulfate Drugs 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
• 125000001113 thiadiazolyl group Chemical group 0.000 description 4
• 230000032258 transport Effects 0.000 description 4
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 229920001268 Cholestyramine Polymers 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 208000035868 Vascular inflammations Diseases 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 3
• 229960004005 amlodipine besylate Drugs 0.000 description 3
• 239000003098 androgen Substances 0.000 description 3
• 230000003143 atherosclerotic effect Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 230000001906 cholesterol absorption Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
• 229960001214 clofibrate Drugs 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 235000019439 ethyl acetate Nutrition 0.000 description 3
• MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 230000002440 hepatic effect Effects 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 229960004400 levonorgestrel Drugs 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 229960004844 lovastatin Drugs 0.000 description 3
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 229940012843 omega-3 fatty acid Drugs 0.000 description 3
• 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 3
• 239000000902 placebo Substances 0.000 description 3
• 229940068196 placebo Drugs 0.000 description 3
• 235000002378 plant sterols Nutrition 0.000 description 3
• 229960002965 pravastatin Drugs 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 229940088594 vitamin Drugs 0.000 description 3
• 235000013343 vitamin Nutrition 0.000 description 3
• 239000011782 vitamin Substances 0.000 description 3
• 229930003231 vitamin Natural products 0.000 description 3
• KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
• OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
• QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
• HFFGOURGAIOQBU-FOWHCLFSSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-ol Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 HFFGOURGAIOQBU-FOWHCLFSSA-N 0.000 description 2
• GEONECATAKDDLT-JDSZYESASA-N (8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol;[(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 GEONECATAKDDLT-JDSZYESASA-N 0.000 description 2
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
• 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 2
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
• TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 2
• 0 **(C(C1(*)N)N*)C1O Chemical compound **(C(C1(*)N)N*)C1O 0.000 description 2
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• VTHUYJIXSMGYOQ-KOORYGTMSA-N 17-hydroxyprogesterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 VTHUYJIXSMGYOQ-KOORYGTMSA-N 0.000 description 2
• 229930182834 17alpha-Estradiol Natural products 0.000 description 2
• QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 2
• 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 2
• VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 2
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
• FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• SKQDKFOTIPJUSV-UHFFFAOYSA-N 4-[2-[[2-hydroxy-3-(2-methylphenoxy)propyl]amino]ethoxy]benzamide Chemical compound CC1=CC=CC=C1OCC(O)CNCCOC1=CC=C(C(N)=O)C=C1 SKQDKFOTIPJUSV-UHFFFAOYSA-N 0.000 description 2
• KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 2
• ARYTXMNEANMLMU-GOMFITQMSA-N 5-alpha-Campestanol Natural products O[C@@H]1C[C@H]2[C@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@@H]([C@@H](CC[C@@H](C(C)C)C)C)CC4)CC3)CC2)CC1 ARYTXMNEANMLMU-GOMFITQMSA-N 0.000 description 2
• OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
• 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
• 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 2
• BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 2
• 229920002905 Colesevelam Polymers 0.000 description 2
• 229920002911 Colestipol Polymers 0.000 description 2
• 241000721047 Danaus plexippus Species 0.000 description 2
• FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
• LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 2
• 229940123583 Factor Xa inhibitor Drugs 0.000 description 2
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010023302 HDL Cholesterol Proteins 0.000 description 2
• 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 238000008214 LDL Cholesterol Methods 0.000 description 2
• 108010028554 LDL Cholesterol Proteins 0.000 description 2
• WQVZLXWQESQGIF-UHFFFAOYSA-N Labetalol hydrochloride Chemical compound Cl.C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 WQVZLXWQESQGIF-UHFFFAOYSA-N 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
• RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 2
• 150000001204 N-oxides Chemical class 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• RETPFDTUCPKFEC-UHFFFAOYSA-N Primidolol Chemical compound CC1=CC=CC=C1OCC(O)CNCCN1C(=O)NC(=O)C(C)=C1 RETPFDTUCPKFEC-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 102000005782 Squalene Monooxygenase Human genes 0.000 description 2
• 108020003891 Squalene monooxygenase Proteins 0.000 description 2
• 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 2
• 108010054082 Sterol O-acyltransferase Proteins 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 229940123464 Thiazolidinedione Drugs 0.000 description 2
• HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
• DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 2
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
• 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
• 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 description 2
• 125000000676 alkoxyimino group Chemical group 0.000 description 2
• 150000003973 alkyl amines Chemical class 0.000 description 2
• 125000005336 allyloxy group Chemical group 0.000 description 2
• QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 229960000528 amlodipine Drugs 0.000 description 2
• 239000003146 anticoagulant agent Substances 0.000 description 2
• 230000036528 appetite Effects 0.000 description 2
• 235000019789 appetite Nutrition 0.000 description 2
• 125000005129 aryl carbonyl group Chemical group 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229960005370 atorvastatin Drugs 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 125000000499 benzofuranyl group Chemical class O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
• 229960003588 bevantolol Drugs 0.000 description 2
• FJTKCFSPYUMXJB-UHFFFAOYSA-N bevantolol hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC[NH2+]CC(O)COC1=CC=CC(C)=C1 FJTKCFSPYUMXJB-UHFFFAOYSA-N 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
• 229960002781 bisoprolol Drugs 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 2
• 229960000932 candesartan Drugs 0.000 description 2
• 229960004349 candesartan cilexetil Drugs 0.000 description 2
• 229960000830 captopril Drugs 0.000 description 2
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
• 239000002327 cardiovascular agent Substances 0.000 description 2
• 229940125692 cardiovascular agent Drugs 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
• 229960004195 carvedilol Drugs 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 2
• RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
• 229960004588 cilostazol Drugs 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 229940035811 conjugated estrogen Drugs 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 125000002993 cycloalkylene group Chemical group 0.000 description 2
• 229940018872 dalteparin sodium Drugs 0.000 description 2
• RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 2
• 229960005316 diltiazem hydrochloride Drugs 0.000 description 2
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
• 229960002768 dipyridamole Drugs 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 238000000921 elemental analysis Methods 0.000 description 2
• QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 2
• 229960005309 estradiol Drugs 0.000 description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 235000021323 fish oil Nutrition 0.000 description 2
• 238000005243 fluidization Methods 0.000 description 2
• 229960003765 fluvastatin Drugs 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229940065346 hydroxyprogesterone acetate Drugs 0.000 description 2
• 230000000260 hypercholesteremic effect Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000031891 intestinal absorption Effects 0.000 description 2
• 230000033227 intestinal cholesterol absorption Effects 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 229960003091 labetalol hydrochloride Drugs 0.000 description 2
• 150000002596 lactones Chemical class 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 230000037356 lipid metabolism Effects 0.000 description 2
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
• 229960002237 metoprolol Drugs 0.000 description 2
• 229960000939 metoprolol succinate Drugs 0.000 description 2
• 239000008239 natural water Substances 0.000 description 2
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
• 229960001597 nifedipine Drugs 0.000 description 2
• 229960000417 norgestimate Drugs 0.000 description 2
• KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 2
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000006014 omega-3 oil Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 229960002582 perindopril Drugs 0.000 description 2
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
• 125000004344 phenylpropyl group Chemical group 0.000 description 2
• 229940068065 phytosterols Drugs 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
• 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
• 229950003568 primidolol Drugs 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 239000000186 progesterone Substances 0.000 description 2
• 229960003387 progesterone Drugs 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• 125000005493 quinolyl group Chemical class 0.000 description 2
• 229960003401 ramipril Drugs 0.000 description 2
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
• SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 229960002909 spirapril Drugs 0.000 description 2
• HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 2
• 108700035424 spirapril Proteins 0.000 description 2
• HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
• 229940032091 stigmasterol Drugs 0.000 description 2
• 235000016831 stigmasterol Nutrition 0.000 description 2
• BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 229940095064 tartrate Drugs 0.000 description 2
• 229960005187 telmisartan Drugs 0.000 description 2
• IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 150000001467 thiazolidinediones Chemical class 0.000 description 2
• 229940064689 tinzaparin sodium Drugs 0.000 description 2
• VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
• 229950003004 tolamolol Drugs 0.000 description 2
• 125000004306 triazinyl group Chemical group 0.000 description 2
• 229940055755 tricor Drugs 0.000 description 2
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
• 229960001641 troglitazone Drugs 0.000 description 2
• 229960000881 verapamil hydrochloride Drugs 0.000 description 2
• DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• KIOUIMVIZXYLFV-BRFIBAHXSA-N (1r,7s,9ar,11ar)-3a-(1-hydroxyprop-2-enyl)-6,6,9a,11a-tetramethyl-1-(6-methylheptan-2-yl)-1,2,4,5,5a,7,8,9,10,11-decahydronaphtho[1,2-g][1]benzofuran-7-ol Chemical compound C([C@]12C)C[C@H](O)C(C)(C)C1CCC1=C2CC[C@]2(C)[C@@H](C(C)CCCC(C)C)COC21C(O)C=C KIOUIMVIZXYLFV-BRFIBAHXSA-N 0.000 description 1
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
• FOZFSEMFCIPOSZ-SPCKQMHLSA-N (2r,3r,4r,5s)-2-(hydroxymethyl)-1-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol;trihydrate Chemical compound O.O.O.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 FOZFSEMFCIPOSZ-SPCKQMHLSA-N 0.000 description 1
• NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 1
• YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
• VMKAFJQFKBASMU-KRWDZBQOSA-N (3as)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole Chemical compound C([C@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-KRWDZBQOSA-N 0.000 description 1
• CHFAFIBYKNQIRA-FYYLOGMGSA-N (3r,4s)-1-(4-fluorophenyl)-4-(4-hydroxyphenyl)-3-(3-oxo-3-phenylpropyl)azetidin-2-one Chemical compound C1=CC(O)=CC=C1[C@H]1N(C=2C=CC(F)=CC=2)C(=O)[C@@H]1CCC(=O)C1=CC=CC=C1 CHFAFIBYKNQIRA-FYYLOGMGSA-N 0.000 description 1
• QRGQONAZHIKMGC-UHFFFAOYSA-N (4-phenoxyphenyl) 4-methylpiperidine-1-carboxylate Chemical compound C1CC(C)CCN1C(=O)OC(C=C1)=CC=C1OC1=CC=CC=C1 QRGQONAZHIKMGC-UHFFFAOYSA-N 0.000 description 1
• QDMNNMIOWVJVLY-MRVPVSSYSA-N (4s)-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1C1=CC=CC=C1 QDMNNMIOWVJVLY-MRVPVSSYSA-N 0.000 description 1
• RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
• MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
• KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
• KIRGLCXNEVICOG-SOFGYWHQSA-N (e)-n-ethyl-6,6-dimethyl-n-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(OCC=2SC=C(C=2)C2=CSC=C2)=C1 KIRGLCXNEVICOG-SOFGYWHQSA-N 0.000 description 1
• JDZOTSLZMQDFLG-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-(2,2-dicyclohexylethyl)piperidine Chemical compound OC(=O)\C=C/C(O)=O.C1CCCNC1CC(C1CCCCC1)C1CCCCC1 JDZOTSLZMQDFLG-BTJKTKAUSA-N 0.000 description 1
• RCNHFUDTRRGRGW-UHFFFAOYSA-N 1,2-benzothiazin-4-one Chemical compound C1=CC=C2C(=O)C=NSC2=C1 RCNHFUDTRRGRGW-UHFFFAOYSA-N 0.000 description 1
• XNJGWTIQYUPOAF-UHFFFAOYSA-N 1,3,2-oxazaborole Chemical compound O1B=NC=C1 XNJGWTIQYUPOAF-UHFFFAOYSA-N 0.000 description 1
• ULNVBRUIKLYGDF-UHFFFAOYSA-N 1,3-bis(4-methylphenyl)thiourea Chemical compound C1=CC(C)=CC=C1NC(=S)NC1=CC=C(C)C=C1 ULNVBRUIKLYGDF-UHFFFAOYSA-N 0.000 description 1
• QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
• ODWXZMXQBDEIBF-UHFFFAOYSA-N 1-(2-cyclohexylphenoxy)-3-(propan-2-ylamino)propan-2-ol;hydron;chloride Chemical compound Cl.CC(C)NCC(O)COC1=CC=CC=C1C1CCCCC1 ODWXZMXQBDEIBF-UHFFFAOYSA-N 0.000 description 1
• MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
• ZFYXOCQUHHETLW-UHFFFAOYSA-N 1-oxo-2-[2,4,6-tri(propan-2-yl)phenyl]ethanesulfonic acid Chemical compound CC(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)CC(=O)S(=O)(=O)O ZFYXOCQUHHETLW-UHFFFAOYSA-N 0.000 description 1
• OICPCODTYMAQOE-UHFFFAOYSA-N 1-phenyl-2,3-dihydropyrrole-5-carboximidamide Chemical compound NC(=N)C1=CCCN1C1=CC=CC=C1 OICPCODTYMAQOE-UHFFFAOYSA-N 0.000 description 1
• CVJRRJMEMYTWRC-UHFFFAOYSA-N 1-phenylpyrrolidine-2-carboximidamide Chemical compound NC(=N)C1CCCN1C1=CC=CC=C1 CVJRRJMEMYTWRC-UHFFFAOYSA-N 0.000 description 1
• BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
• GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• NUNZGJKXTJMXGY-UHFFFAOYSA-N 1H-indole-2-carboximidamide Chemical compound C1=CC=C2NC(C(=N)N)=CC2=C1 NUNZGJKXTJMXGY-UHFFFAOYSA-N 0.000 description 1
• FSUPKDUNLKQBCN-UHFFFAOYSA-N 1H-pyrrole-2-carboximidamide Chemical compound NC(=N)C1=CC=CN1 FSUPKDUNLKQBCN-UHFFFAOYSA-N 0.000 description 1
• JKCHHDHEHOKKQP-UHFFFAOYSA-N 1h-imidazol-2-ylboronic acid Chemical compound OB(O)C1=NC=CN1 JKCHHDHEHOKKQP-UHFFFAOYSA-N 0.000 description 1
• TWWNPUZQYVWXJY-UHFFFAOYSA-N 1h-quinazoline-4-thione Chemical compound C1=CC=C2C(S)=NC=NC2=C1 TWWNPUZQYVWXJY-UHFFFAOYSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 description 1
• ZTHSAEXVSBEBHE-BDQAORGHSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid;hydrochloride Chemical compound Cl.O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 ZTHSAEXVSBEBHE-BDQAORGHSA-N 0.000 description 1
• KGVYOGLFOPNPDJ-UHFFFAOYSA-N 2-[2-(4,5-diphenyl-1h-imidazol-2-yl)phenoxy]-n,n-dimethylethanamine Chemical compound CN(C)CCOC1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 KGVYOGLFOPNPDJ-UHFFFAOYSA-N 0.000 description 1
• JECYUBVRTQDVAT-UHFFFAOYSA-N 2-acetylphenol Chemical class CC(=O)C1=CC=CC=C1O JECYUBVRTQDVAT-UHFFFAOYSA-N 0.000 description 1
• ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
• MOWNMUBBANQCKS-UHFFFAOYSA-N 2-imidazolidin-1-ylpyrimidine Chemical class C1NCCN1C1=NC=CC=N1 MOWNMUBBANQCKS-UHFFFAOYSA-N 0.000 description 1
• ZBLJEMQEPGCCJA-UHFFFAOYSA-N 2-phenyl-1,2-oxazolidine-3-carboximidamide Chemical compound NC(=N)C1CCON1C1=CC=CC=C1 ZBLJEMQEPGCCJA-UHFFFAOYSA-N 0.000 description 1
• FKMCYKOPRFRZDN-UHFFFAOYSA-N 3,1-benzoxazine-4-thione Chemical compound C1=CC=C2C(=S)OC=NC2=C1 FKMCYKOPRFRZDN-UHFFFAOYSA-N 0.000 description 1
• HYTIPJFUWHYQON-UHFFFAOYSA-N 3,4-dihydro-1h-quinoxalin-2-one Chemical compound C1=CC=C2NC(=O)CNC2=C1 HYTIPJFUWHYQON-UHFFFAOYSA-N 0.000 description 1
• TVXOXGBTADZYCZ-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenyl-1h-imidazol-2-yl)sulfanyl]pentyl]-1-heptylurea Chemical compound C=1C=C(F)C=C(F)C=1NC(=O)N(CCCCCCC)CCCCCSC(N1)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 TVXOXGBTADZYCZ-UHFFFAOYSA-N 0.000 description 1
• QKJLDOBXDUVGEE-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea Chemical compound C=1C=C(F)C=C(F)C=1NC(=O)N(CCCCCCC)CC1=CC=C(CC(C)(C)C)C=C1 QKJLDOBXDUVGEE-UHFFFAOYSA-N 0.000 description 1
• LGHBWDKMGOIZKH-CBZIJGRNSA-N 3-Deoxyestrone Chemical compound C1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 LGHBWDKMGOIZKH-CBZIJGRNSA-N 0.000 description 1
• JIMXJAFZPUUCAD-UHFFFAOYSA-N 3-benzyl-1,3-thiazolidine-2,4-dione Chemical class O=C1CSC(=O)N1CC1=CC=CC=C1 JIMXJAFZPUUCAD-UHFFFAOYSA-N 0.000 description 1
• MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
• CIPBQTCSXVEDSG-UHFFFAOYSA-N 4,5-bis(4-methoxyphenyl)-2-(trifluoromethyl)-1,3-thiazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)SC(C(F)(F)F)=N1 CIPBQTCSXVEDSG-UHFFFAOYSA-N 0.000 description 1
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
• MXNQOXJLUJUCGE-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 MXNQOXJLUJUCGE-UHFFFAOYSA-N 0.000 description 1
• KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
• DNTDOBSIBZKFCP-UHFFFAOYSA-N 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2h-naphthalen-1-one;hydron;chloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-UHFFFAOYSA-N 0.000 description 1
• MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
• RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
• KNKBZYUINRTEOG-UHFFFAOYSA-M 6-bromohexyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCCBr KNKBZYUINRTEOG-UHFFFAOYSA-M 0.000 description 1
• XZRKEDHJXXLVSK-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;6-phenylpteridine-2,4,7-triamine Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 XZRKEDHJXXLVSK-UHFFFAOYSA-N 0.000 description 1
• VGLGVJVUHYTIIU-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3-[(prop-2-enylthio)methyl]-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(CSCC=C)NS2(=O)=O VGLGVJVUHYTIIU-UHFFFAOYSA-N 0.000 description 1
• NLLMJANWPUQQTA-UBDQQSCGSA-N 7,8-didehydro-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-UBDQQSCGSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
• 239000000775 AMPA receptor antagonist Substances 0.000 description 1
• 229940123324 Acyltransferase inhibitor Drugs 0.000 description 1
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
• 241000156724 Antirhea Species 0.000 description 1
• 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
• 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
• 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
• 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
• 102000018616 Apolipoproteins B Human genes 0.000 description 1
• 108010027006 Apolipoproteins B Proteins 0.000 description 1
• 102000013918 Apolipoproteins E Human genes 0.000 description 1
• 108010025628 Apolipoproteins E Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 235000007319 Avena orientalis Nutrition 0.000 description 1
• 244000075850 Avena orientalis Species 0.000 description 1
• 229940123208 Biguanide Drugs 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
• 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 1
• 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 1
• ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
• 244000303965 Cyamopsis psoralioides Species 0.000 description 1
• RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• HMXRXBIGGYUEAX-SFHVURJKSA-N Evodiamine Natural products CN1[C@H]2N(CCc3[nH]c4ccccc4c23)C(=O)c5ccccc15 HMXRXBIGGYUEAX-SFHVURJKSA-N 0.000 description 1
• 229940082863 Factor VIIa inhibitor Drugs 0.000 description 1
• PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
• 102000004864 Fibroblast growth factor 10 Human genes 0.000 description 1
• 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
• 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
• 229920001499 Heparinoid Polymers 0.000 description 1
• 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
• 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
• ODCZJZWSXPVLAW-KXCGKLMDSA-N Hymeglusin Chemical compound OC(=O)/C=C(\C)/C=C(C)/C[C@H](C)CCCC[C@H]1OC(=O)[C@@H]1CO ODCZJZWSXPVLAW-KXCGKLMDSA-N 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 229940125922 IBAT inhibitor Drugs 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• LNXBEIZREVRNTF-UHFFFAOYSA-N Lifibrol Chemical compound C1=CC(C(C)(C)C)=CC=C1CCC(O)COC1=CC=C(C(O)=O)C=C1 LNXBEIZREVRNTF-UHFFFAOYSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 229940127470 Lipase Inhibitors Drugs 0.000 description 1
• 229940127308 Microsomal Triglyceride Transfer Protein Inhibitors Drugs 0.000 description 1
• IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
• JXRAXHBVZQZSIC-JKVLGAQCSA-N Moexipril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 JXRAXHBVZQZSIC-JKVLGAQCSA-N 0.000 description 1
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
• XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• HPUKOXOQHIMLHG-MERQFXBCSA-N N[C@@H](CCN1CC2=CC(C=NN)=CC=C2)C1=O.OC(C(F)(F)F)=O Chemical compound N[C@@H](CCN1CC2=CC(C=NN)=CC=C2)C1=O.OC(C(F)(F)F)=O HPUKOXOQHIMLHG-MERQFXBCSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 102000007530 Neurofibromin 1 Human genes 0.000 description 1
• 108010085793 Neurofibromin 1 Proteins 0.000 description 1
• KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
• BIMQSYXGQFKQPR-BOXHHOBZSA-N OC(=O)C(F)(F)F.NN=CC1=CC=CC(CN2C([C@@H](NS(=O)(=O)C=3C=C4C=CC=CC4=CC=3)CC2)=O)=C1 Chemical compound OC(=O)C(F)(F)F.NN=CC1=CC=CC(CN2C([C@@H](NS(=O)(=O)C=3C=C4C=CC=CC4=CC=3)CC2)=O)=C1 BIMQSYXGQFKQPR-BOXHHOBZSA-N 0.000 description 1
• PNFKRMLGYMIFMQ-BDQAORGHSA-N OC(=O)C(F)(F)F.NN=CC1=CC=CC(CN2C([C@@H](NS(=O)(=O)N3CC4=CC=CC=C4CC3)CC2)=O)=C1 Chemical compound OC(=O)C(F)(F)F.NN=CC1=CC=CC(CN2C([C@@H](NS(=O)(=O)N3CC4=CC=CC=C4CC3)CC2)=O)=C1 PNFKRMLGYMIFMQ-BDQAORGHSA-N 0.000 description 1
• FMTGJHHLSBHFOO-UHFFFAOYSA-N OC1NC2(CC2)C1P Chemical compound OC1NC2(CC2)C1P FMTGJHHLSBHFOO-UHFFFAOYSA-N 0.000 description 1
• 108010044210 PPAR-beta Proteins 0.000 description 1
• BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
• 101710117029 Peroxisome proliferator-activated receptor delta Proteins 0.000 description 1
• 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
• VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 1
• 244000134552 Plantago ovata Species 0.000 description 1
• 235000003421 Plantago ovata Nutrition 0.000 description 1
• 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 239000009223 Psyllium Substances 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 108091006614 SLC10A2 Proteins 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 102000000019 Sterol Esterase Human genes 0.000 description 1
• 108010055297 Sterol Esterase Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• RKSMVPNZHBRNNS-UHFFFAOYSA-N Succinobucol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(SC(C)(C)SC=2C=C(C(OC(=O)CCC(O)=O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 RKSMVPNZHBRNNS-UHFFFAOYSA-N 0.000 description 1
• 229940100389 Sulfonylurea Drugs 0.000 description 1
• 244000186561 Swietenia macrophylla Species 0.000 description 1
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
• 244000269722 Thea sinensis Species 0.000 description 1
• 241000534944 Thia Species 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
• STZJJZZLAXIFHB-DIRPKPHOSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dio Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 STZJJZZLAXIFHB-DIRPKPHOSA-N 0.000 description 1
• OZPWNCNLFBVVEN-RFYLDXRNSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(9s,13s,14s)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;[(8r,9 Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1.OS(=O)(=O)OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 OZPWNCNLFBVVEN-RFYLDXRNSA-N 0.000 description 1
• 229960002632 acarbose Drugs 0.000 description 1
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229960002122 acebutolol Drugs 0.000 description 1
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
• KTUFKADDDORSSI-UHFFFAOYSA-N acebutolol hydrochloride Chemical compound Cl.CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 KTUFKADDDORSSI-UHFFFAOYSA-N 0.000 description 1
• 229960003830 acebutolol hydrochloride Drugs 0.000 description 1
• 229960001466 acetohexamide Drugs 0.000 description 1
• VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 229960003526 acipimox Drugs 0.000 description 1
• 229940062328 actos Drugs 0.000 description 1
• 239000002404 acyltransferase inhibitor Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 description 1
• 229960003103 alfuzosin hydrochloride Drugs 0.000 description 1
• 125000004419 alkynylene group Chemical group 0.000 description 1
• OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
• 239000002160 alpha blocker Substances 0.000 description 1
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
• 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
• 229950007522 altizide Drugs 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229960003555 anagrelide hydrochloride Drugs 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 229940094957 androgens and estrogen Drugs 0.000 description 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
• SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 229940069428 antacid Drugs 0.000 description 1
• 239000003159 antacid agent Substances 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000004004 anti-anginal agent Substances 0.000 description 1
• 229940124345 antianginal agent Drugs 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 229940127226 anticholesterol agent Drugs 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
• 229960003856 argatroban Drugs 0.000 description 1
• VGYPZLGWVQQOST-JUERRSSISA-N ascofuranone Chemical class OC=1C(Cl)=C(C)C(C=O)=C(O)C=1C\C=C(/C)CC\C=C(/C)[C@@H]1CC(=O)C(C)(C)O1 VGYPZLGWVQQOST-JUERRSSISA-N 0.000 description 1
• 229960002274 atenolol Drugs 0.000 description 1
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
• 229940062310 avandia Drugs 0.000 description 1
• 229940058139 aygestin Drugs 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 150000003851 azoles Chemical class 0.000 description 1
• IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 description 1
• 229950000017 befloxatone Drugs 0.000 description 1
• VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
• 229960003619 benazepril hydrochloride Drugs 0.000 description 1
• MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 description 1
• 229960004067 benazeprilat Drugs 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 229960001541 benzthiazide Drugs 0.000 description 1
• NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
• XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
• 235000013734 beta-carotene Nutrition 0.000 description 1
• 239000011648 beta-carotene Substances 0.000 description 1
• TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
• 229960002747 betacarotene Drugs 0.000 description 1
• 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• 150000004283 biguanides Chemical class 0.000 description 1
• SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• LHMHCLYDBQOYTO-UHFFFAOYSA-N bromofluoromethane Chemical compound FCBr LHMHCLYDBQOYTO-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229960004111 buformin Drugs 0.000 description 1
• XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 229950001261 camiglibose Drugs 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 description 1
• 229950006044 caroxazone Drugs 0.000 description 1
• FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
• 229960002165 carteolol hydrochloride Drugs 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 229940062399 cenestin Drugs 0.000 description 1
• 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
• 229960005110 cerivastatin Drugs 0.000 description 1
• SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
• GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
• UWCBNAVPISMFJZ-UHFFFAOYSA-N cetamolol Chemical compound CNC(=O)COC1=CC=CC=C1OCC(O)CNC(C)(C)C UWCBNAVPISMFJZ-UHFFFAOYSA-N 0.000 description 1
• 229950003205 cetamolol Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• WRJDCGFHAICFLO-NXVVXOECSA-N chembl75797 Chemical compound C1=C(OC)C(OC)=CC=C1CC\N=C\1N(C)CCC/1 WRJDCGFHAICFLO-NXVVXOECSA-N 0.000 description 1
• 229960000437 chlorothiazide sodium Drugs 0.000 description 1
• 229960001761 chlorpropamide Drugs 0.000 description 1
• 230000031154 cholesterol homeostasis Effects 0.000 description 1
• 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
• JNDJPKHYZWRRIS-UHFFFAOYSA-N cicloprolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1OCCOCC1CC1 JNDJPKHYZWRRIS-UHFFFAOYSA-N 0.000 description 1
• 229950003775 cicloprolol Drugs 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229950003072 clinofibrate Drugs 0.000 description 1
• 229960002925 clonidine hydrochloride Drugs 0.000 description 1
• SUAJWTBTMNHVBZ-UHFFFAOYSA-N clonitrate Chemical compound [O-][N+](=O)OCC(CCl)O[N+]([O-])=O SUAJWTBTMNHVBZ-UHFFFAOYSA-N 0.000 description 1
• 229950004347 clonitrate Drugs 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 229960003958 clopidogrel bisulfate Drugs 0.000 description 1
• FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
• 229960000674 colesevelam hydrochloride Drugs 0.000 description 1
• 229940097479 colestid Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000003218 coronary vasodilator agent Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
• 229960003176 cyclothiazide Drugs 0.000 description 1
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
• PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 1
• 229960004776 danaparoid sodium Drugs 0.000 description 1
• QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
• 229950006689 darglitazone Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 229960004597 dexfenfluramine Drugs 0.000 description 1
• ZMRUPTIKESYGQW-PFEQFJNWSA-N dexpropranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OC[C@H](O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-PFEQFJNWSA-N 0.000 description 1
• GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
• 229960001912 dicoumarol Drugs 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 229960004890 diethylpropion Drugs 0.000 description 1
• XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• WQVZLXWQESQGIF-WJKBNZMCSA-N dilevalol hydrochloride Chemical compound Cl.C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 WQVZLXWQESQGIF-WJKBNZMCSA-N 0.000 description 1
• QMMFVYPAHWMCMS-UHFFFAOYSA-N dimethylsulfide Substances CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
• 150000002016 disaccharides Chemical group 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 150000004863 dithiolanes Chemical class 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
• VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
• 229960000220 doxazosin mesylate Drugs 0.000 description 1
• HTAFVGKAHGNWQO-UHFFFAOYSA-N droprenilamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1CCCCC1 HTAFVGKAHGNWQO-UHFFFAOYSA-N 0.000 description 1
• 229950011072 droprenilamine Drugs 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
• 229960000309 enalapril maleate Drugs 0.000 description 1
• 229950002375 englitazone Drugs 0.000 description 1
• 229960005153 enoxaparin sodium Drugs 0.000 description 1
• 230000010235 enterohepatic circulation Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229960002179 ephedrine Drugs 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• 229960003013 epoprostenol sodium Drugs 0.000 description 1
• SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
• 229960001015 esmolol hydrochloride Drugs 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• NLLMJANWPUQQTA-SPUZQDLCSA-N estra-1,3,5(10),7-tetraene-3,17alpha-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-SPUZQDLCSA-N 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
• HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
• HXFPJNUAYGFFAE-UHFFFAOYSA-N ethyl 2-(4-chlorophenoxy)-2-methoxypropanoate Chemical compound ClC1=CC=C(OC(C(=O)OCC)(C)OC)C=C1 HXFPJNUAYGFFAE-UHFFFAOYSA-N 0.000 description 1
• FUBBWDWIGBTUPQ-UHFFFAOYSA-N ethyl 2-[4-[3-[(4-fluorophenyl)-hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylanilino]-2-oxoacetate Chemical compound CC1=CC(NC(=O)C(=O)OCC)=CC(C)=C1OC1=CC=C(O)C(C(O)C=2C=CC(F)=CC=2)=C1 FUBBWDWIGBTUPQ-UHFFFAOYSA-N 0.000 description 1
• ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 229960003580 felodipine Drugs 0.000 description 1
• 229940006346 femhrt Drugs 0.000 description 1
• 229960001582 fenfluramine Drugs 0.000 description 1
• 229940020832 fenofibrate 200 mg Drugs 0.000 description 1
• 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 125000001207 fluorophenyl group Chemical group 0.000 description 1
• CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
• 229960004038 fluvoxamine Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 229960002598 fumaric acid Drugs 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 239000002554 heparinoid Substances 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• 238000002657 hormone replacement therapy Methods 0.000 description 1
• 229960002003 hydrochlorothiazide Drugs 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 230000000055 hyoplipidemic effect Effects 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 239000004026 insulin derivative Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 229960002198 irbesartan Drugs 0.000 description 1
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
• 229960000201 isosorbide dinitrate Drugs 0.000 description 1
• MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
• 229960003827 isosorbide mononitrate Drugs 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 229950010270 itazigrel Drugs 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 108010077695 lipolysis-stimulated receptor Proteins 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 150000004668 long chain fatty acids Chemical class 0.000 description 1
• 229940063720 lopid Drugs 0.000 description 1
• 229960000519 losartan potassium Drugs 0.000 description 1
• 239000003055 low molecular weight heparin Substances 0.000 description 1
• 229940127215 low-molecular weight heparin Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 229940098895 maleic acid Drugs 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229940099690 malic acid Drugs 0.000 description 1
• 235000013310 margarine Nutrition 0.000 description 1
• 239000003264 margarine Substances 0.000 description 1
• 235000019988 mead Nutrition 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 229940103185 mefenamate Drugs 0.000 description 1
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
• 229950004994 meglitinide Drugs 0.000 description 1
• 229940101513 menest Drugs 0.000 description 1
• IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
• 229960001390 mestranol Drugs 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229960001252 methamphetamine Drugs 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
• CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
• JCAZSWWHFJVFPP-UHFFFAOYSA-N methyl 5-chloro-5-oxopentanoate Chemical compound COC(=O)CCCC(Cl)=O JCAZSWWHFJVFPP-UHFFFAOYSA-N 0.000 description 1
• 229960001566 methyltestosterone Drugs 0.000 description 1
• 229940099246 mevacor Drugs 0.000 description 1
• 229960001110 miglitol Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229950005607 mixidine Drugs 0.000 description 1
• YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 229960004185 moexipril hydrochloride Drugs 0.000 description 1
• XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
• 229960004027 molsidomine Drugs 0.000 description 1
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
• BXJUYPRTOQQTSS-UHFFFAOYSA-N n-[1-[[3-(aminomethyl)phenyl]methyl]-5-oxopyrrolidin-3-yl]dibenzofuran-2-sulfonamide Chemical compound NCC1=CC=CC(CN2C(CC(C2)NS(=O)(=O)C=2C=C3C4=CC=CC=C4OC3=CC=2)=O)=C1 BXJUYPRTOQQTSS-UHFFFAOYSA-N 0.000 description 1
• RRLYGXRMVLYFNX-UHFFFAOYSA-N n-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;hydron;chloride Chemical compound Cl.CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1C(C)=O RRLYGXRMVLYFNX-UHFFFAOYSA-N 0.000 description 1
• 229960004255 nadolol Drugs 0.000 description 1
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 229960000619 nebivolol Drugs 0.000 description 1
• 229940033757 niaspan Drugs 0.000 description 1
• 229960000827 niceritrol Drugs 0.000 description 1
• FUWFSXZKBMCSKF-ZASNTINBSA-N nicofuranose Chemical compound C([C@]1(O)[C@H]([C@H](OC(=O)C=2C=NC=CC=2)[C@@H](COC(=O)C=2C=NC=CC=2)O1)OC(=O)C=1C=NC=CC=1)OC(=O)C1=CC=CN=C1 FUWFSXZKBMCSKF-ZASNTINBSA-N 0.000 description 1
• 229960004552 nicofuranose Drugs 0.000 description 1
• LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
• 229960002497 nicorandil Drugs 0.000 description 1
• 229960005366 nilvadipine Drugs 0.000 description 1
• 229960000715 nimodipine Drugs 0.000 description 1
• 229960000227 nisoldipine Drugs 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229940099990 ogen Drugs 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
• 229960001243 orlistat Drugs 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• DUQOOLBWGUKRAJ-UHFFFAOYSA-N oxagrelate Chemical compound OCC1=NNC(=O)C2=C(C)C(C(=O)OCC)=C(C)C=C21 DUQOOLBWGUKRAJ-UHFFFAOYSA-N 0.000 description 1
• 229950004599 oxagrelate Drugs 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 1
• 150000007978 oxazole derivatives Chemical class 0.000 description 1
• 150000002916 oxazoles Chemical class 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 229960001834 oxprenolol hydrochloride Drugs 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 229950008492 pentopril Drugs 0.000 description 1
• BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 1
• 229950006286 pentrinitrol Drugs 0.000 description 1
• 229960004803 perhexiline maleate Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960003006 phenoxybenzamine hydrochloride Drugs 0.000 description 1
• 229960003562 phentermine Drugs 0.000 description 1
• 229960003424 phenylacetic acid Drugs 0.000 description 1
• 239000003279 phenylacetic acid Substances 0.000 description 1
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
• 229960000395 phenylpropanolamine Drugs 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 229960002827 pioglitazone hydrochloride Drugs 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229940089484 pravachol Drugs 0.000 description 1
• WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
• 229960002386 prazosin hydrochloride Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229940063238 premarin Drugs 0.000 description 1
• 229960001989 prenylamine Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 229940087667 prometrium Drugs 0.000 description 1
• YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 1
• 229960003402 propatylnitrate Drugs 0.000 description 1
• 229960004604 propranolol hydrochloride Drugs 0.000 description 1
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• 229940063222 provera Drugs 0.000 description 1
• 229940070687 psyllium Drugs 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical group OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
• 150000003219 pyrazolines Chemical class 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 229940073095 questran Drugs 0.000 description 1
• IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
• 229960003042 quinapril hydrochloride Drugs 0.000 description 1
• 229960000213 ranolazine Drugs 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 229960002354 repaglinide Drugs 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229960003271 rosiglitazone maleate Drugs 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 235000017709 saponins Nutrition 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 235000011649 selenium Nutrition 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 229940091258 selenium supplement Drugs 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
• 229960004425 sibutramine Drugs 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 150000003378 silver Chemical class 0.000 description 1
• 238000011125 single therapy Methods 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• WOHSQDNIXPEQAE-QBKVZTCDSA-M sodium;3-[2-[[(1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate Chemical compound [Na+].CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC([O-])=O)=N1 WOHSQDNIXPEQAE-QBKVZTCDSA-M 0.000 description 1
• CPIWHAFLBZQYLQ-UHFFFAOYSA-N sodium;6-chloro-1,1-dioxo-1$l^{6},2,4-benzothiadiazin-2-ide-7-sulfonamide Chemical compound [Na+].N1=C[N-]S(=O)(=O)C2=C1C=C(Cl)C(S(=O)(=O)N)=C2 CPIWHAFLBZQYLQ-UHFFFAOYSA-N 0.000 description 1
• LMJQCTISQYSLPF-CMZLOHJFSA-M sodium;[(8r,9s,13s,14s,17s)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 LMJQCTISQYSLPF-CMZLOHJFSA-M 0.000 description 1
• VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
• 229960003579 sotalol hydrochloride Drugs 0.000 description 1
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
• 229960002256 spironolactone Drugs 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 229940031439 squalene Drugs 0.000 description 1
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
• 239000004059 squalene synthase inhibitor Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
• 229960003329 sulfinpyrazone Drugs 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 1
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
• CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
• 229960002961 ticlopidine hydrochloride Drugs 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 229960005221 timolol maleate Drugs 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 229960002277 tolazamide Drugs 0.000 description 1
• OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
• 229960005371 tolbutamide Drugs 0.000 description 1
• 229960002309 toloxatone Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 229950001407 trifenagrel Drugs 0.000 description 1
• SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 229960001722 verapamil Drugs 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• 229940111503 welchol Drugs 0.000 description 1
• GOWCWQHQMNLGEB-UHFFFAOYSA-M zinc;fluorobenzene;chloride Chemical compound [Zn+]Cl.FC1=CC=[C-]C=C1 GOWCWQHQMNLGEB-UHFFFAOYSA-M 0.000 description 1
• 229940072168 zocor Drugs 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
• 150000003952 β-lactams Chemical class 0.000 description 1